Indicator type;Execution Sectors;Total
Units carrying out R&D in Biotechnology;Total;1.636
Units carrying out R&D in Biotechnology;Companies;113
Units carrying out R&D in Biotechnology;Public Administration;68
Units carrying out R&D in Biotechnology;Higher Education;1.444
Units carrying out R&D in Biotechnology;NPPI;11
% Units by type of biotechnology used: Genetic Code;Total;37,2
% Units by type of biotechnology used: Genetic Code;Companies;87,6
% Units by type of biotechnology used: Genetic Code;Public Administration;94,1
% Units by type of biotechnology used: Genetic Code;Higher Education;30,7
% Units by type of biotechnology used: Genetic Code;NPPI;27,3
% Units by type of biotechnology used: Functional Units;Total;43,5
% Units by type of biotechnology used: Functional Units;Companies;86,7
% Units by type of biotechnology used: Functional Units;Public Administration;95,6
% Units by type of biotechnology used: Functional Units;Higher Education;37,6
% Units by type of biotechnology used: Functional Units;NPPI;54,5
% Units by type of biotechnology used: Cell and Tissue Culture and Engineering;Total;27,6
% Units by type of biotechnology used: Cell and Tissue Culture and Engineering;Companies;72,6
% Units by type of biotechnology used: Cell and Tissue Culture and Engineering;Public Administration;80,9
% Units by type of biotechnology used: Cell and Tissue Culture and Engineering;Higher Education;21,3
% Units by type of biotechnology used: Cell and Tissue Culture and Engineering;NPPI;63,6
% Units by type of biotechnology used: Bioprocesses;Total;53,6
% Units by type of biotechnology used: Bioprocesses;Companies;65,5
% Units by type of biotechnology used: Bioprocesses;Public Administration;91,2
% Units by type of biotechnology used: Bioprocesses;Higher Education;50,9
% Units by type of biotechnology used: Bioprocesses;NPPI;54,5
% Units by type of biotechnology used: Subcellular Organisms;Total;13,9
% Units by type of biotechnology used: Subcellular Organisms;Companies;55,8
% Units by type of biotechnology used: Subcellular Organisms;Public Administration;64,7
% Units by type of biotechnology used: Subcellular Organisms;Higher Education;8,1
% Units by type of biotechnology used: Subcellular Organisms;NPPI;36,4
% Units by type of biotechnology used: Bioinformatics;Total;28,7
% Units by type of biotechnology used: Bioinformatics;Companies;71,7
% Units by type of biotechnology used: Bioinformatics;Public Administration;83,8
% Units by type of biotechnology used: Bioinformatics;Higher Education;22,6
% Units by type of biotechnology used: Bioinformatics;NPPI;36,4
% Units by type of biotechnology used: Nanobiotechnology;Total;15,5
% Units by type of biotechnology used: Nanobiotechnology;Companies;53,1
% Units by type of biotechnology used: Nanobiotechnology;Public Administration;73,5
% Units by type of biotechnology used: Nanobiotechnology;Higher Education;9,8
% Units by type of biotechnology used: Nanobiotechnology;NPPI;18,2
% Units by type of biotechnology used: Other;Total;15,7
% Units by type of biotechnology used: Other;Companies;7,1
% Units by type of biotechnology used: Other;Public Administration;7,3
% Units by type of biotechnology used: Other;Higher Education;16,9
% Units by type of biotechnology used: Other;NPPI;9,1
Units in which biotechnology activities are: Main and/or exclusive;Total;676
Units in which biotechnology activities are: Main and/or exclusive;Companies;35
Units in which biotechnology activities are: Main and/or exclusive;Public Administration;5
Units in which biotechnology activities are: Main and/or exclusive;Higher Education;629
Units in which biotechnology activities are: Main and/or exclusive;NPPI;7
Units in which biotechnology activities are: A secondary business line;Total;347
Units in which biotechnology activities are: A secondary business line;Companies;36
Units in which biotechnology activities are: A secondary business line;Public Administration;47
Units in which biotechnology activities are: A secondary business line;Higher Education;262
Units in which biotechnology activities are: A secondary business line;NPPI;2
Units in which biotechnology activities are: A necessary tool for production;Total;613
Units in which biotechnology activities are: A necessary tool for production;Companies;42
Units in which biotechnology activities are: A necessary tool for production;Public Administration;16
Units in which biotechnology activities are: A necessary tool for production;Higher Education;553
Units in which biotechnology activities are: A necessary tool for production;NPPI;2
% Units by final application areas of biotechnology use: Human Health;Total;48,7
% Units by final application areas of biotechnology use: Human Health;Companies;76,1
% Units by final application areas of biotechnology use: Human Health;Public Administration;92,7
% Units by final application areas of biotechnology use: Human Health;Higher Education;44,3
% Units by final application areas of biotechnology use: Human Health;NPPI;72,7
% Units by final application areas of biotechnology use: Animal Health and Aquaculture;Total;17,8
% Units by final application areas of biotechnology use: Animal Health and Aquaculture;Companies;18,6
% Units by final application areas of biotechnology use: Animal Health and Aquaculture;Public Administration;61,8
% Units by final application areas of biotechnology use: Animal Health and Aquaculture;Higher Education;15,8
% Units by final application areas of biotechnology use: Animal Health and Aquaculture;NPPI;9,1
% Units by final application areas of biotechnology use: Food Products;Total;32,4
% Units by final application areas of biotechnology use: Food Products;Companies;26,6
% Units by final application areas of biotechnology use: Food Products;Public Administration;82,3
% Units by final application areas of biotechnology use: Food Products;Higher Education;30,7
% Units by final application areas of biotechnology use: Food Products;NPPI;0
% Units by final application areas of biotechnology use: Agriculture and Forestry;Total;26,4
% Units by final application areas of biotechnology use: Agriculture and Forestry;Companies;21,2
% Units by final application areas of biotechnology use: Agriculture and Forestry;Public Administration;67,7
% Units by final application areas of biotechnology use: Agriculture and Forestry;Higher Education;24,9
% Units by final application areas of biotechnology use: Agriculture and Forestry;NPPI;18,2
% Units by final application areas of biotechnology use: Environment;Total;19,8
% Units by final application areas of biotechnology use: Environment;Companies;23,9
% Units by final application areas of biotechnology use: Environment;Public Administration;75
% Units by final application areas of biotechnology use: Environment;Higher Education;16,9
% Units by final application areas of biotechnology use: Environment;NPPI;9,1
% Units by final application areas of biotechnology use: Industry;Total;15,2
% Units by final application areas of biotechnology use: Industry;Companies;18,6
% Units by final application areas of biotechnology use: Industry;Public Administration;66,2
% Units by final application areas of biotechnology use: Industry;Higher Education;12,6
% Units by final application areas of biotechnology use: Industry;NPPI;9,1
R&D personnel in Biotechnology (PP);Total;50.084
R&D personnel in Biotechnology (PP);Companies;15.563
R&D personnel in Biotechnology (PP);Public Administration;16.597
R&D personnel in Biotechnology (PP);Higher Education;17.743
R&D personnel in Biotechnology (PP);NPPI;181
R&D personnel in Biotechnology (PP): Research personnel;Total;32.396
R&D personnel in Biotechnology (PP): Research personnel;Companies;9.798
R&D personnel in Biotechnology (PP): Research personnel;Public Administration;13.026
R&D personnel in Biotechnology (PP): Research personnel;Higher Education;9.445
R&D personnel in Biotechnology (PP): Research personnel;NPPI;127
R&D personnel in Biotechnology (PP): Technical and auxiliary personnel;Total;17.688
R&D personnel in Biotechnology (PP): Technical and auxiliary personnel;Companies;5.765
R&D personnel in Biotechnology (PP): Technical and auxiliary personnel;Public Administration;3.571
R&D personnel in Biotechnology (PP): Technical and auxiliary personnel;Higher Education;8.298
R&D personnel in Biotechnology (PP): Technical and auxiliary personnel;NPPI;54
R&D personnel in Biotechnology (PP). Women;Total;28.401
R&D personnel in Biotechnology (PP). Women;Companies;9.804
R&D personnel in Biotechnology (PP). Women;Public Administration;8.578
R&D personnel in Biotechnology (PP). Women;Higher Education;9.907
R&D personnel in Biotechnology (PP). Women;NPPI;112
R&D personnel in Biotechnology (PP). Women: Research personnel;Total;17.461
R&D personnel in Biotechnology (PP). Women: Research personnel;Companies;5.851
R&D personnel in Biotechnology (PP). Women: Research personnel;Public Administration;6.435
R&D personnel in Biotechnology (PP). Women: Research personnel;Higher Education;5.104
R&D personnel in Biotechnology (PP). Women: Research personnel;NPPI;71
R&D personnel in Biotechnology (PP). Women: Technical and auxiliary personnel;Total;10.939
R&D personnel in Biotechnology (PP). Women: Technical and auxiliary personnel;Companies;3.953
R&D personnel in Biotechnology (PP). Women: Technical and auxiliary personnel;Public Administration;2.143
R&D personnel in Biotechnology (PP). Women: Technical and auxiliary personnel;Higher Education;4.802
R&D personnel in Biotechnology (PP). Women: Technical and auxiliary personnel;NPPI;41
R&D personnel in Biotechnology (FTE);Total;35.301,2
R&D personnel in Biotechnology (FTE);Companies;11.442,1
R&D personnel in Biotechnology (FTE);Public Administration;10.721,9
R&D personnel in Biotechnology (FTE);Higher Education;12.993,4
R&D personnel in Biotechnology (FTE);NPPI;143,8
R&D personnel in Biotechnology (FTE): Research personnel;Total;22.324,6
R&D personnel in Biotechnology (FTE): Research personnel;Companies;6.766,8
R&D personnel in Biotechnology (FTE): Research personnel;Public Administration;8.386,7
R&D personnel in Biotechnology (FTE): Research personnel;Higher Education;7.069,9
R&D personnel in Biotechnology (FTE): Research personnel;NPPI;101,2
R&D personnel in Biotechnology (FTE): Technical and auxiliary personnel;Total;12.976,7
R&D personnel in Biotechnology (FTE): Technical and auxiliary personnel;Companies;4.675,3
R&D personnel in Biotechnology (FTE): Technical and auxiliary personnel;Public Administration;2.335,2
R&D personnel in Biotechnology (FTE): Technical and auxiliary personnel;Higher Education;5.923,6
R&D personnel in Biotechnology (FTE): Technical and auxiliary personnel;NPPI;42,6
R&D personnel in Biotechnology (FTE). Women;Total;20.474,8
R&D personnel in Biotechnology (FTE). Women;Companies;7.280,8
R&D personnel in Biotechnology (FTE). Women;Public Administration;5.633,9
R&D personnel in Biotechnology (FTE). Women;Higher Education;7.471,8
R&D personnel in Biotechnology (FTE). Women;NPPI;88,3
R&D personnel in Biotechnology (FTE). Women: Research personnel;Total;12.176,5
R&D personnel in Biotechnology (FTE). Women: Research personnel;Companies;4.080,5
R&D personnel in Biotechnology (FTE). Women: Research personnel;Public Administration;4.171,9
R&D personnel in Biotechnology (FTE). Women: Research personnel;Higher Education;3.870,1
R&D personnel in Biotechnology (FTE). Women: Research personnel;NPPI;54
R&D personnel in Biotechnology (FTE). Women: Technical and auxiliary personnel;Total;8.298,2
R&D personnel in Biotechnology (FTE). Women: Technical and auxiliary personnel;Companies;3.200,3
R&D personnel in Biotechnology (FTE). Women: Technical and auxiliary personnel;Public Administration;1.462
R&D personnel in Biotechnology (FTE). Women: Technical and auxiliary personnel;Higher Education;3.601,6
R&D personnel in Biotechnology (FTE). Women: Technical and auxiliary personnel;NPPI;34,3
Expenditure on internal R&D in Biotechnology (thousands of euros);Total;2.565.367
Expenditure on internal R&D in Biotechnology (thousands of euros);Companies;775.164
Expenditure on internal R&D in Biotechnology (thousands of euros);Public Administration;554.906
Expenditure on internal R&D in Biotechnology (thousands of euros);Higher Education;1.223.801
Expenditure on internal R&D in Biotechnology (thousands of euros);NPPI;11.496
1) By type of expenditure: Current expenditure;Total;2.359.528
1) By type of expenditure: Current expenditure;Companies;727.099
1) By type of expenditure: Current expenditure;Public Administration;513.043
1) By type of expenditure: Current expenditure;Higher Education;1.108.189
1) By type of expenditure: Current expenditure;NPPI;11.197
1.1) Labour expenditure of research personnel;Total;950.162
1.1) Labour expenditure of research personnel;Companies;267.235
1.1) Labour expenditure of research personnel;Public Administration;318.977
1.1) Labour expenditure of research personnel;Higher Education;360.922
1.1) Labour expenditure of research personnel;NPPI;3.027
1.2) Labour expenditure of technical and auxiliary personnel;Total;421.784
1.2) Labour expenditure of technical and auxiliary personnel;Companies;128.800
1.2) Labour expenditure of technical and auxiliary personnel;Public Administration;71.268
1.2) Labour expenditure of technical and auxiliary personnel;Higher Education;220.540
1.2) Labour expenditure of technical and auxiliary personnel;NPPI;1.176
1.3) Other current expenditure;Total;987.583
1.3) Other current expenditure;Companies;331.063
1.3) Other current expenditure;Public Administration;122.798
1.3) Other current expenditure;Higher Education;526.727
1.3) Other current expenditure;NPPI;6.994
2) By type of expenditure: Capital expenditure;Total;205.839
2) By type of expenditure: Capital expenditure;Companies;48.066
2) By type of expenditure: Capital expenditure;Public Administration;41.862
2) By type of expenditure: Capital expenditure;Higher Education;115.612
2) By type of expenditure: Capital expenditure;NPPI;299
2.1) Land and buildings;Total;30.577
2.1) Land and buildings;Companies;6.521
2.1) Land and buildings;Public Administration;7.162
2.1) Land and buildings;Higher Education;16.843
2.1) Land and buildings;NPPI;52
2.2) Equipment and tools;Total;136.544
2.2) Equipment and tools;Companies;39.416
2.2) Equipment and tools;Public Administration;33.362
2.2) Equipment and tools;Higher Education;63.527
2.2) Equipment and tools;NPPI;239
2.3) Acquisition of specific R&D software;Total;7.117
2.3) Acquisition of specific R&D software;Companies;1.945
2.3) Acquisition of specific R&D software;Public Administration;1.211
2.3) Acquisition of specific R&D software;Higher Education;3.959
2.3) Acquisition of specific R&D software;NPPI;3
2.4) Other R&D-specific IP products;Total;31.601
2.4) Other R&D-specific IP products;Companies;184
2.4) Other R&D-specific IP products;Public Administration;128
2.4) Other R&D-specific IP products;Higher Education;31.284
2.4) Other R&D-specific IP products;NPPI;5
1.1) By origin of funds: Own funds;Total;1.030.214
1.1) By origin of funds: Own funds;Companies;78.546
1.1) By origin of funds: Own funds;Public Administration;90.048
1.1) By origin of funds: Own funds;Higher Education;860.603
1.1) By origin of funds: Own funds;NPPI;1.016
1.2) By origin of funds: Funds from the Business sector;Total;277.770
1.2) By origin of funds: Funds from the Business sector;Companies;115.144
1.2) By origin of funds: Funds from the Business sector;Public Administration;27.808
1.2) By origin of funds: Funds from the Business sector;Higher Education;128.002
1.2) By origin of funds: Funds from the Business sector;NPPI;6.816
1.3) By origin of funds: Funds from the Public Administration sector;Total;951.439
1.3) By origin of funds: Funds from the Public Administration sector;Companies;458.700
1.3) By origin of funds: Funds from the Public Administration sector;Public Administration;372.119
1.3) By origin of funds: Funds from the Public Administration sector;Higher Education;119.498
1.3) By origin of funds: Funds from the Public Administration sector;NPPI;1.122
1.4) By origin of funds: Funds from the Higher Education sector;Total;4.307
1.4) By origin of funds: Funds from the Higher Education sector;Companies;1.537
1.4) By origin of funds: Funds from the Higher Education sector;Public Administration;2.122
1.4) By origin of funds: Funds from the Higher Education sector;Higher Education;647
1.4) By origin of funds: Funds from the Higher Education sector;NPPI;0
1.5) By origin of funds: Funds from the Private Non-Profit Institutions sector;Total;52.107
1.5) By origin of funds: Funds from the Private Non-Profit Institutions sector;Companies;28.686
1.5) By origin of funds: Funds from the Private Non-Profit Institutions sector;Public Administration;9.445
1.5) By origin of funds: Funds from the Private Non-Profit Institutions sector;Higher Education;12.986
1.5) By origin of funds: Funds from the Private Non-Profit Institutions sector;NPPI;990
1.6) By origin of funds: Funds from the rest of the world;Total;249.530
1.6) By origin of funds: Funds from the rest of the world;Companies;92.551
1.6) By origin of funds: Funds from the rest of the world;Public Administration;53.363
1.6) By origin of funds: Funds from the rest of the world;Higher Education;102.065
1.6) By origin of funds: Funds from the rest of the world;NPPI;1.551
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros);Total;171.660
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros);Companies;35.006
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros);Public Administration;13.038
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros);Higher Education;123.396
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros);NPPI;220
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In Spain;Total;131.863
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In Spain;Companies;30.282
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In Spain;Public Administration;12.385
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In Spain;Higher Education;88.985
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In Spain;NPPI;212
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In the rest of the world;Total;39.797
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In the rest of the world;Companies;4.725
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In the rest of the world;Public Administration;653
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In the rest of the world;Higher Education;34.412
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In the rest of the world;NPPI;8
% Units that consider the following obstacles to the development of biotechnologies as very important: Access to capital;Total;41,8
% Units that consider the following obstacles to the development of biotechnologies as very important: Access to capital;Companies;57,5
% Units that consider the following obstacles to the development of biotechnologies as very important: Access to capital;Public Administration;52,9
% Units that consider the following obstacles to the development of biotechnologies as very important: Access to capital;Higher Education;39,8
% Units that consider the following obstacles to the development of biotechnologies as very important: Access to capital;NPPI;72,7
% Units that consider the following obstacles to the development of biotechnologies as very important: Access to technology/information;Total;14,8
% Units that consider the following obstacles to the development of biotechnologies as very important: Access to technology/information;Companies;8,8
% Units that consider the following obstacles to the development of biotechnologies as very important: Access to technology/information;Public Administration;14,7
% Units that consider the following obstacles to the development of biotechnologies as very important: Access to technology/information;Higher Education;15,3
% Units that consider the following obstacles to the development of biotechnologies as very important: Access to technology/information;NPPI;9,1
% Units that consider the following obstacles to the development of biotechnologies as very important: Access to human resources;Total;24,5
% Units that consider the following obstacles to the development of biotechnologies as very important: Access to human resources;Companies;46
% Units that consider the following obstacles to the development of biotechnologies as very important: Access to human resources;Public Administration;36,8
% Units that consider the following obstacles to the development of biotechnologies as very important: Access to human resources;Higher Education;22,3
% Units that consider the following obstacles to the development of biotechnologies as very important: Access to human resources;NPPI;18,2
% Units that consider the following obstacles to the development of biotechnologies as very important: Disconnection from the value chain;Total;13,8
% Units that consider the following obstacles to the development of biotechnologies as very important: Disconnection from the value chain;Companies;23
% Units that consider the following obstacles to the development of biotechnologies as very important: Disconnection from the value chain;Public Administration;35,3
% Units that consider the following obstacles to the development of biotechnologies as very important: Disconnection from the value chain;Higher Education;12,1
% Units that consider the following obstacles to the development of biotechnologies as very important: Disconnection from the value chain;NPPI;9,1
% Units that consider the following obstacles to the development of biotechnologies as very important: Lack of access to international markets;Total;19
% Units that consider the following obstacles to the development of biotechnologies as very important: Lack of access to international markets;Companies;28,3
% Units that consider the following obstacles to the development of biotechnologies as very important: Lack of access to international markets;Public Administration;44,1
% Units that consider the following obstacles to the development of biotechnologies as very important: Lack of access to international markets;Higher Education;17,1
% Units that consider the following obstacles to the development of biotechnologies as very important: Lack of access to international markets;NPPI;27,3
% Units that consider the following obstacles to the development of biotechnologies as very important: Lack of distribution and marketing channels;Total;19,4
% Units that consider the following obstacles to the development of biotechnologies as very important: Lack of distribution and marketing channels;Companies;28,3
% Units that consider the following obstacles to the development of biotechnologies as very important: Lack of distribution and marketing channels;Public Administration;38,2
% Units that consider the following obstacles to the development of biotechnologies as very important: Lack of distribution and marketing channels;Higher Education;17,8
% Units that consider the following obstacles to the development of biotechnologies as very important: Lack of distribution and marketing channels;NPPI;18,2
% Units that consider the following obstacles to the development of biotechnologies as very important: Public acceptance/perception;Total;15,3
% Units that consider the following obstacles to the development of biotechnologies as very important: Public acceptance/perception;Companies;10,6
% Units that consider the following obstacles to the development of biotechnologies as very important: Public acceptance/perception;Public Administration;10,3
% Units that consider the following obstacles to the development of biotechnologies as very important: Public acceptance/perception;Higher Education;16
% Units that consider the following obstacles to the development of biotechnologies as very important: Public acceptance/perception;NPPI;9,1
% Units that consider the following obstacles to the development of biotechnologies as very important: Legal and regulatory requirements;Total;41,3
% Units that consider the following obstacles to the development of biotechnologies as very important: Legal and regulatory requirements;Companies;40,7
% Units that consider the following obstacles to the development of biotechnologies as very important: Legal and regulatory requirements;Public Administration;39,7
% Units that consider the following obstacles to the development of biotechnologies as very important: Legal and regulatory requirements;Higher Education;41,4
% Units that consider the following obstacles to the development of biotechnologies as very important: Legal and regulatory requirements;NPPI;36,4
% Units that consider the following obstacles to the development of biotechnologies as very important: Time/cost;Total;51,2
% Units that consider the following obstacles to the development of biotechnologies as very important: Time/cost;Companies;62,8
% Units that consider the following obstacles to the development of biotechnologies as very important: Time/cost;Public Administration;51,5
% Units that consider the following obstacles to the development of biotechnologies as very important: Time/cost;Higher Education;50,2
% Units that consider the following obstacles to the development of biotechnologies as very important: Time/cost;NPPI;63,6
% Units that consider the following obstacles to the development of biotechnologies as very important: Difficult access to patenting;Total;20
% Units that consider the following obstacles to the development of biotechnologies as very important: Difficult access to patenting;Companies;19,5
% Units that consider the following obstacles to the development of biotechnologies as very important: Difficult access to patenting;Public Administration;19,1
% Units that consider the following obstacles to the development of biotechnologies as very important: Difficult access to patenting;Higher Education;20,1
% Units that consider the following obstacles to the development of biotechnologies as very important: Difficult access to patenting;NPPI;18,2